Mark H. Corrigan

Dr. Mark Corrigan is the Chairman of Blackthorn Therapeutics, a clinical stage biopharmaceutical company developing targeted treatments for neurobehavioral disorders.

Prior to BlackThorn, Mark was as CEO of Zalicus, leading them through their merger with Epirus. Mark joined the specialty pharmaceutical company Sepracor in 2003 and served as their executive vice president of research and development until December 2009, where he was responsible for the clinical development of several successful CNS programs, including Lunesta. Prior to joining Sepracor, Mark spent 10 years with Pharmacia & Upjohn, where he was most recently group vice president of Global Clinical Research and Experimental Medicine.

Before Mark entered the pharmaceutical industry, he spent five years in academic research at the University of North Carolina focusing on psychoneuroendocrinology and maintains an adjunct faculty appointment as in the Psychiatry Dept. He is a distinguished fellow of the American Psychiatric Association.

Mark serves on the Board of Cardiome Pharma Corporation, Quartet Medicine, Synereca Pharmaceuticals, and Pamlico Biopharma (both Acele Biopharma companies). He had served on the board of directors of CoLucid, and at Cubist Pharmaceuticals and Avanir Pharmaceuticals where he also chaired the scientific advisory committees.

Mark holds a B.A. and M.D. from the University of Virginia and received specialty training in psychiatry at Maine Medical Center and Cornell University.